G1 Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Good afternoon, everyone, and thank you for joining us at the second day of the Needham and Company Healthcare Conference. My name is Gil Blum and I am a senior biotech analyst here at Needham & Company, and I cover oncology and immuno-oncology subsectors.
It is my pleasure to have with me today, Jack Bailey, the CEO of G1 Therapeutics. (Conference Instructions) So maybe a bit of an introduction, just for people who are not familiar with G1. Just talk to us a little bit about COSELA, the drug class that you're developing, and what is the general potential in oncology here.
Yeah. Well first of all, thank you for having us today, Gil, at the Needham Health Conference. Really excited to be here.
In terms of G1, it was a company founded in 2008. One of our two founders was Dr. Ned Sharpless who many people may know, he went on to run the National Cancer Institute. Had a vision for fundamentally transforming the chemotherapy experience. Intelligently designed
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
